Baying for a flexible drug price.
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000191:economics* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics*; D005252:Fees, Pharmaceutical; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib